Drugs / BD211
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06465550 | Jan 2024 → Dec 2026 expected | beta thalassemia | Shanghai BDgene Co., Ltd. | Recruiting | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT05773729 | Sep 2023 → Mar 2026 overdue | beta thalassemia | Shanghai BDgene Co., Ltd. | Recruiting | No outcome recorded |
| — | NCT05776173 | Aug 2023 → Mar 2026 overdue | beta-thalassemia major | Shanghai BDgene Co., Ltd. | Recruiting | No outcome recorded |
| — | NCT05015920 | Jul 2021 → Aug 2024 | hematologic disorder | Shanghai BDgene Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BD211 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05776173 ↗ |
| Action | Restore | “designed to produce healthy β-globin in red blood cells” NCT05773729 ↗ |
| Modality | Cell therapy | “autologous CD34+ hematopoietic stem cells” NCT05773729 ↗ |
| Route | Intravenous | “via a single IV administration” NCT05015920 ↗ |